Search Results

Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use

OJ L 121, 01/05/2001, p. 34–44 (ES, DA, DE, EL, EN, FR, IT, NL, PT, FI, SV)
This document has been published in a special edition(s) ( CS, ET, LV, LT, HU, MT, PL, SK, SL, BG, RO, HR)

OJ L 121, 01/05/2001, p. 34–44

Latest consolidated version:

01/01/2022

COMMISSION STAFF WORKING DOCUMENT IMPACT ASSESSMENT REPORT Accompanying the document Proposal for a Regulation of the European Parliament and of the Council on standards of quality and safety for substances of human origin intended for human application and repealing Directives 2002/98/EC and 2004/23/EC

SWD/2022/190 final

Judgment of the General Court (Seventh Chamber) of 7 March 2013.
Acino AG (formerly Acino Pharma GmbH) v European Commission.
Medicinal products for human use — Suspension of the placing on the market and withdrawal of medicinal products containing the active ingredient Clopidogrel — Variation of the authorisation to place on the market — Prohibition from placing medicinal products on the market — Regulation (EC) No 726/2004 and Directive 2001/83/EC — Proportionality — Obligation to state reasons.
Case T‑539/10.

European Court Reports 2013 -00000

ECLI identifier: ECLI:EU:T:2013:110

Agreement on the European Economic Area - Annex II - Technical Regulations, standards, testing and certification - List provided for in Article 23

OJ L 1, 03/01/1994, p. 263–320 (ES, DA, DE, EL, EN, FR, IT, NL, PT)

OJ L 1, 03/01/1994, p. 263–320

Decision of the EEA Joint Committee No 23/2004 of 19 March 2004 amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement

OJ L 127, 29/04/2004, p. 128–129 (ES, DA, DE, EL, EN, FR, IT, NL, PT, FI, SV)
This document has been published in a special edition(s) ( CS, ET, LV, LT, HU, MT, PL, SK, SL, BG, RO, HR)

OJ L 127, 29/04/2004, p. 128–129

Directive 2004/24/EC of the European Parliament and of the Council of 31 March 2004 amending, as regards traditional herbal medicinal products, Directive 2001/83/EC on the Community code relating to medicinal products for human use

OJ L 136, 30/04/2004, p. 85–90 (ES, DA, DE, EL, EN, FR, IT, NL, PT, FI, SV)
This document has been published in a special edition(s) ( CS, ET, LV, LT, HU, MT, PL, SK, SL, BG, RO, HR)

OJ L 136, 30/04/2004, p. 85–90

Commission Directive 2003/94/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use (Text with EEA relevance)

OJ L 262, 14/10/2003, p. 22–26 (ES, DA, DE, EL, EN, FR, IT, NL, PT, FI, SV)
This document has been published in a special edition(s) ( CS, ET, LV, LT, HU, MT, PL, SK, SL, BG, RO, HR)

OJ L 262, 14/10/2003, p. 22–26

Judgment of the General Court (Seventh Chamber) of 7 March 2013.
Acino AG (formerly Acino Pharma GmbH) v European Commission.
Medicinal products for human use — Suspension of the placing on the market and withdrawal of medicinal products containing the active ingredient Clopidogrel — Variation of the authorisation to place on the market — Prohibition from placing medicinal products on the market — Regulation (EC) No 726/2004 and Directive 2001/83/EC — Proportionality — Obligation to state reasons.
Case T‑539/10.

WRITTEN QUESTION No. 2335/96 by Hiltrud BREYER to the Commission. BSE and medicinal products

OJ C 83, 14/03/1997, p. 10 (ES, DA, DE, EL, EN, FR, IT, NL, PT)

OJ C 83, 14/03/1997, p. 10

WRITTEN QUESTION No. 3537/93 by Alexandros ALAVANOS to the Commission. Blood and blood products contaminated with the AIDS virus

OJ C 340, 05/12/1994, p. 41 (ES, DA, DE, EL, EN, FR, IT, NL, PT)

OJ C 340, 05/12/1994, p. 41